Merck tried to alter hypertension “guidelines” to favor Cozaar. That’s pretty shameful.
Related posts:
- Nurses as the latest drug reps
- Hypertension and the DASH diet
- Prescribing insulin for diabetes, do endocrinologists have a financial incentive to do so?
- Living with cancer
- The "mid-adult woman"
- Bad time to be a drug rep
- Merck calls off the wolves
KevinMD.com on Facebook
{ 4 comments }
Clearly tort reform is the only answer. The only reason Merck would do something like this is because of a horrible legal climate! Hopefully the AMA will be on the case soon.
Wyeth (amiodarone) and Genentech (Tpa) have infiltrated and influenced the American Heart Association (AHA). Even the super smart, brilliant, legend in his own mind, Elliot bought that one hook, line, and sinker. Trickery and deceipt is everywhere when money is involved.
Yes, this is just being to get some air time over here at last:
http://nhsblogdoc.blogspot.com/2006/02/its-those-drug-companies-again-take.html
The excellent site: NO FREE LUNCH was pointed out to me by an AMerican physician – and there is a branch in the UK as well.
Scary stuff
John
Also problematic is the issue of certain medical specialty societies or entities writing clinical “guidelines” that may not be applicable or practicle to practice in other settings, such as the ER
Comments on this entry are closed.